Immunotherapy holds promise for multiple myeloma (MM) patients but little is known about how MM-induced immunosuppression influences response to therapy. Here, we investigated the impact of disease progression on immunotherapy efficacy in the Vk*MYC mouse model. Treatment with agonistic anti-CD137 (4-1BB) mAbs efficiently protected mice when administered early but failed to contain MM growth when delayed more than three weeks after Vk*MYC tumor cell challenge. The quality of CD8 + T cell response to CD137 stimulation was not altered by the presence of MM, but CD8 + T cell numbers were profoundly reduced at the time of treatment. Our data suggest that an insufficient ratio of CD8 + T cells over MM cells (CD8/MM) accounts for the loss of anti-CD137 mAb efficacy. We established serum M-protein levels prior to therapy as a predictive factor of response. Moreover, we developed an in silico model to capture the dynamic interactions between CD8 + T cells and MM cells. Finally, we explored two methods to improve the CD8/MM ratio: anti-CD137 mAb immunotherapy combined with Treg-depletion or administered after chemotherapy treatment with cyclophosphamide or melphalan efficiently reduced MM burden and prolonged survival. Altogether, our data indicate that consolidation treatment with anti-CD137 mAbs might prevent MM relapse.
Introduction
Multiple myeloma (MM) is a hematological malignancy where clonal plasma cells secreting monoclonal proteins (M-proteins) proliferate in the bone marrow (BM). Standard treatment options include autologous stem cell transplantation for eligible patients, as well as alkylating agents such as cyclophosphamide, proteasome inhibitors such as bortezomib and immunomodulatory drugs (IMiDs) (1) . Despite high response rates to standard therapies, most MM patients relapse and eventually succumb to the disease. Therefore, new therapeutic options with different mechanisms of action are urgently needed to eradicate residual disease and achieve long-term remission.
A variety of immune-based therapies are now being explored, with the potential to overcome MM cell resistance to conventional drugs (2) . Elotozumab (anti-SLAMF7) and daratumumab (anti-CD38) are two monoclonal antibodies (mAbs) that were FDA approved in 2015 for the treatment of relapsed/refractory MM patients (3) . These mAbs target molecules expressed on MM cells and exert their anti-tumor effect through multiple mechanisms including immune-modulation. Many other immunebased strategies are currently in development, such as bispecific antibodies, infusions of ex vivo expanded/activated autologous T or NK cells, TCR-modified T cells and chimeric antigen-receptor T and NK cells (4) . Immune checkpoint inhibition is also considered for the treatment of MM. A phase I clinical study reported disease stabilization, but no objective response, in relapsed/refractory MM patients treated with single agent anti-PD-1 blocking mAb nivolumab (5) . Moreover, in spite of encouraging response rates, a phase II clinical study examining the anti-PD-1 mAb pembrolizumab in combination with IMiDs had to be terminated due to increased risk of severe adverse events (6) .
Agonistic mAbs targeting costimulatory molecules represent an alternative to checkpoint inhibitors (7) . CD137 (4-1BB) is a co-stimulatory molecule expressed on activated T cells and NK cells as well as antigen presenting cells and endothelial cells (8) . Upon ligation, CD137 signals through nuclear factor (NF)-κB and the MAPK cascade to promote cell survival, proliferation and enhanced effector functions (9) . Recent evidence indicates that CD137 costimulation augments the mitochondrial mass of CD8 + T cells (10) . CD137 costimulation also induces chromatin remodeling and thereby imprints long-term changes in CD8 + T cells (11) .
Results

Early anti-CD137 mAb treatment induces potent effector T cell responses and protects mice against MM with negligible toxicity.
To evaluate the efficacy of anti-CD137 mAbs against MM, we challenged C57BL/6 WT mice with Vk12653 (Vk*MYC) MM cells followed by 2-week treatment with anti-CD137 mAbs starting from 2 weeks after tumor inoculation. Anti-CD137 mAb treatment significantly prolonged the survival of MMchallenged mice, with 68% (13/20) of the anti-CD137 mAb-treated mice becoming long-term survivors ( Figure 1A) . Moreover, monoclonal gammopathy at week 5 post Vk*MYC cell-injection was clearly reduced in anti-CD137 mAb-treated mice ( Figure 1B ). Mice treated with anti-CD137 mAbs harbored significantly reduced numbers of MM cells ( Figure 1C ), and increased numbers of CD8 + T cells and FoxP3 -CD4 + T helper cells in the BM and spleen ( Figures 1D and E) . These data confirm our previous findings that anti-CD137 mAbs induce massive T cell expansion and provide long-term protection against MM (12) .
To gain further insight into the quality of the T cell response induced following anti-CD137 mAb treatment, cytokine production was analyzed by intracellular staining. We found that anti-CD137 mAb treatment increased the percentage of IFNγand TNF-producing CD4 + and CD8 + T cells in the BM and spleen (Figures 2A and B) . We also observed an increase in IL10-producing T cells, with BM CD4 + T cells being the most important IL10 producers. Moreover, we analyzed the memory status of BM CD8 + T cells and observed a large increase in CD44 + CD62Leffector/effector-memory cells (TEM) following anti-CD137 mAb injection into both tumor-naïve and MM-bearing mice ( Figure 2C and Supplemental Figure 1 ).
Since the potent T cell responses induced by anti-CD137 mAbs may lead to tissue damage, and notably hepatotoxicity (21) , we measured serum levels of the liver enzymes alanine transaminase (ALT) and aspartate transaminase (AST) as well as T cell and tumor cell infiltration of the liver. AST levels were significantly increased in control IgG-but not anti-CD137 mAb-treated mice (Supplemental Figure 2A ), probably reflecting liver damage caused by the tumor (Supplemental Figure 2B ). The livers of anti-CD137 mAb-treated mice harbored very low numbers of MM cells but showed increased lymphocytic infiltrates, including CD8 + T cells and FoxP3 + Tregs (Supplemental Figure 2 , B-F). Overall, anti-CD137 mAb treated mice appeared healthy and we did not observe obvious external signs of autoimmunity nor inflammation. Taken together, these data indicate that anti-CD137 mAbs induce strong effector T cell responses that efficiently protect mice against MM with negligible liver damage.
CD137 stimulation induces transient NK cell responses followed by T cell proliferation and IFNγ production.
We previously reported that, in the Vk*MYC MM model, therapeutic efficacy of anti-CD137 mAbs requires the presence of both NK cells and CD8 + T cells (12) . To gain further insight into the kinetics of lymphocyte responses to CD137 stimulation, tumor-naïve WT mice were given a single injection of anti-CD137 mAbs on day 0, and NK cell and T cell proliferation and IFNγ production were analyzed in the BM and spleen on day 1, 3 and 7. By day 3 post anti-CD137 mAb injection, NK cell responses had reached their maximum and we observed a significant increase in the percentages of proliferating and IFNγ-producing NK cells when compared with IgG-treated mice (Figure 3 , A-D and Supplemental Figure   3 , A-B). By contrast, on day 3, percentages of proliferative CD4 + and CD8 + T cells were only slightly increased in anti-CD137 mAb treated mice and there was virtually no change in IFNγ production compared to control IgG treated mice. However, on day 7, we observed strong T cell proliferation and IFNγ production in mice that had received anti-CD137 mAbs. We also measured systemic levels of IFNγ and observed a slight increase on day 7 post-CD137 mAb injection (Supplemental Figure 3C ). Of note, the magnitude of T cell responses was higher in the BM (Figure 3 , A-D) than in the spleen (Supplemental Figure 3 , A-B). In agreement with previous reports (22) (23) (24) , we observed reduced numbers and percentages of NK cells in mice injected with anti-CD137 mAbs (Figure 3 , E-F). This decrease was more striking in the spleen than in the BM. We obtained similar results when NK cells were gated either as TCRβ -NK1.1 + or TCRβ -NKp46 + cells (data not shown). Altogether, these data indicate that NK cells are the first lymphocytes to respond to CD137 stimulation, but NK cell responses are transient. By day 7 post anti-CD137 mAb injection, the majority of NK cells had disappeared while T cells showed robust proliferation and IFNγ production.
IFNγ signaling is required for CD8 + T cell expansion and optimal efficacy of anti-CD137 mAb therapy.
To investigate the importance of IFN-signaling for CD8 + T responses to CD137 stimulation, tumor-naïve WT, Ifnγ -/or Ifnγr -/mice received a 2-week anti-CD137 mAb-treatment. We observed a large increase in CD8 + T cell numbers in the BM and spleen of anti-CD137 mAb-treated WT mice whereas CD8 + T cell expansion in response to anti-CD137 mAb treatment was compromised in the spleen of Ifnγ -/mice and in the BM and spleen of Ifnγr -/mice ( Figure 4A and Supplemental Figure 4A ). Yet, percentages of CD44 + CD62L -TEM CD8 + T cell were increased in Ifnγr -/mice following anti-CD137 mAb treatment (Supplemental Figure 4B ), indicating that, in spite of their limited expansion, CD8 + T cells do respond to CD137 stimulation in the absence of IFNγ-signaling. By contrast, anti-CD137 mAb-treatment increased the numbers of BM CD8 + T in Ifnar -/mice, indicating that type I IFNs are not essential for CD8 + T expansion following CD137 stimulation (Supplemental Figure 4C ).
Next, we analyzed the IFN-requirement of anti-CD137 mAbs for their anti-MM effect. We observed that the efficacy of anti-CD137 mAbs against MM was compromised in Ifnγ -/mice ( Figure 4B ). Interestingly, lack of treatment efficacy was associated with decreased CD8 + T cell numbers in the BM of anti-CD137 mAb treated Ifnγ -/mice compared to WT mice ( Figure 4C ) as well as increased IL10 production by CD4 + T cells (Figure 4 , D-E). Of note, anti-CD137 mAb treatment could not be tested in Ifnγr -/mice because these mice failed to develop MM when challenged with Vk*MYC MM cells (data not shown), probably because of high circulating levels of IFNγ (Supplemental Figure 4D ). In agreement with their ability to expand CD8 + T cells in the absence of type I IFN signaling, anti-CD137 mAbs efficiently protected Ifnar -/mice against MM (Supplemental Figure 4E ). All together, these data demonstrate that IFNγ contributes to CD8 + T cell expansion and is essential for efficient anti-CD137 mAb therapy in the Vk*MYC mouse model of MM.
Anti-CD137 mAb-treatment loses efficacy when delayed more than 3 weeks after Vk*MYC cell-
challenge.
So far, our data have established that anti-CD137 mAb-treatment efficiently protects against MM when given at week 2 post-Vk*MYC cell challenge. At this time point, a very low percentage of MM cells (<1%) is detectable in the BM and the tumor has not yet spread to the spleen (Supplemental Figures 5A and  B ). To determine whether anti-CD137 mAb treatment could be delayed to treat advanced disease stages, MM-challenged WT mice were given a 2-week anti-CD137 mAb treatment starting from week 1, 2, 3 or 4 after Vk*MYC cell injection (Supplemental Figure 5C ). Tumor burden and serum M-protein level analyses indicated that anti-CD137 mAb treatment lost efficacy when delayed more than 3 weeks after Vk*MYC cell injection ( Figures 5A and B ).
We hypothesized that MM-induced immunosuppression might contribute to the loss of anti-CD137 mAb efficacy. To gain more insight into the course of natural immune responses to MM, we analyzed IFNγ production by NK cells and T cells in the BM of MM-bearing mice. Interestingly, in mice with low-tumor burden (< 4.8 x 10 5 MM cells), we observed a positive correlation between percentages of IFNγproducing CD8 + T cells and tumor burden in the BM whereas this correlation became negative in mice with higher tumor burden (> 4.8 x 10 5 MM cells; Figure 5C ). By contrast, no correlation was found between the percentages of IFNγ-producing NK cells or CD4 + T cells and tumor burden in the BM (Supplemental Figure 5D ). These data indicate that the developing tumor may trigger an initial CD8 + T cell response but this response is then suppressed as the tumor grows. Moreover, percentages of CD4 + and CD8 + T cells producing the immunosuppressive cytokine IL10 positively correlated with tumor burden in the BM ( Figure 5D ), thereby supporting the idea of progressive immunosuppression. These data suggest that the establishment of a suppressive microenvironment might contribute to the loss of efficacy of anti-CD137 mAbs against MM.
High MM burden does not prevent T cells from responding to CD137 stimulation
To determine whether MM-induced immunosuppression hampers immune cell ability to respond to CD137 stimulation, we analyzed NK cell and T cell responses to a single injection of anti-CD137 mAbs given either at week 2 or at week 4 post Vk*MYC cell challenge. These 2 time points were chosen because very good therapeutic efficacy of anti-CD137 mAbs was obtained at week 2 and protection was lost at week 4 ( Figures 5A and B ). Intriguingly, while NK cell numbers significantly dropped in response to week-2-anti-CD137 mAb injection, this decrease was much less pronounced at week 4 post Vk*MYC cell challenge (Supplemental Figures 6A and B) . Importantly, anti-CD137 mAbs induced T cell proliferation and IFNγ production when given either at week 2 or week 4 post Vk*MYC cell challenge (Figures 6A and B and Supplemental Figures 6C and D) . Moreover, there was no correlation between percentages of IFNγ-producing CD4 + or CD8 + T cells and tumor burden in mice that had received a 2-week-anti-CD137 mAb treatment (Supplemental Figure 6E ). Still, we observed a positive correlation between tumor burden and percentages of IL10-producing CD4 + but not CD8 + T cells in these mice (Supplemental Figure 6F ). Of note, most of IL10-producing CD4 + T cells were also positive for IFNγ (Supplemental Figures 6G and H) . Altogether, these data indicate that T cell exhaustion is unlikely to be the reason for the lack of treatment efficacy; in high-tumor burden bearing mice, CD4 + and CD8 + T cells are still able to respond to CD137 stimulation by proliferating vigorously and by producing IFNγ.
Reduced numbers of CD8 + T cells in association with high-tumor burden might contribute to the lack of efficacy of delayed anti-CD137 mAb treatment.
Even though equivalent CD8 + T cell proliferation was observed in response to week 2 or week 4 anti-CD137 mAb injection, we noticed that the numbers of BM CD8 + T cells obtained post-CD137 stimulation were lower when this injection was given at week 4 ( Figure 6C ). In the BM of untreated mice, CD8 + T cell numbers dropped drastically when the tumor-burden reached 10 6 malignant plasma cells per femur ( Figure 6D ). Thus, in mice with high tumor burden, low numbers of BM CD8 + T cells prior to anti-CD137 mAb therapy will result in low numbers of CD8 + T cells post-therapy, in spite of CD137-induced CD8 + T cell proliferation. Of note, the fold increase in CD8 + T cell numbers induced by CD137 stimulation at week 2 was higher than the one at week 4 (increased 4.2 and 1.5 times, respectively), indicating that increased CD8 + T cell death might occur at week 4. Furthermore, the ratio of CD8 + T cells over MM cells (CD8/MM) decreases with time post MM-injection: before week 3 post-MM injection, most of the mice had a CD8/MM ratio above 1 whereas after week 4 this ratio dropped below 1 ( Figure 6E ). These data support the idea that insufficient CD8/MM ratio contributes to the lack of efficacy of delayed anti-CD137 mAb treatment.
Serum M-protein levels before treatment predict the efficacy of anti-CD137 mAbs
We hypothesized that tumor burden prior to treatment may be a predictive factor of anti-CD137 mAb treatment efficacy. To test this hypothesis, we divided mice into responders and non-responders (Supplemental Figure 7A ) and performed a logistic regression of response versus pre-treatment Mprotein levels ( Figure 7A and Supplemental Figure 7B ). This logistic model correctly classified 15/17 (88%) responders as responders and 8/10 (80%) non-responders as non-responders. This model indicates that mice displaying pre-treatment M-protein levels below 7.3% are likely to respond to anti-CD137 mAb treatment (predicted efficacy of 95%) whereas treatment would fail in mice with initial Mproteins levels above 29.4% (predicted failure rate of 95%). Moreover, a partition tree performed on the same data set and using a cut-off value of 10.2% for pre-treatment M-protein levels correctly identified 15 of 17 responders and all 10 non-responders ( Figure 7B ). Overall these analyses indicate that treatment efficacy depends on initial tumor burden.
In silico modeling of CD8 + T cell-MM cell interactions and their impact on treatment efficacy
To further understand the interactions between CD8 + T cells and MM cells in the BM, we developed a Interactions between these populations are regulated by different parameters such as MM and CD8 + T cell growth rates, conversion rates of naïve into activated CD8 + T cells and of activated into exhausted CD8 + T cells, killing capacity of activated CD8 + T cells and MM suppressive effect (see Supplemental methods). We first selected parameters so that the 4 population dynamics reflected the data we obtained in untreated mice. In these settings, MM tumor grew very slowly until day 21 and then increased rapidly to reach a plateau around day 60 ( Figure 8A ). In parallel, numbers of naïve CD8 + T cells decreased due to their conversion into activated CD8 + T cells and the suppressive effect of the tumor. The activated CD8 + T cell population increased up to day 12 but as MM grew, these cells were suppressed and converted into exhausted CD8 + T cells that finally died, leading to a profound decrease in total CD8 + T cell numbers. We then defined the best fitting parameters for anti-CD137 mAb treatment under the assumption that this therapy will induce further conversion of naïve CD8 + T cells into activated CD8 + T cells and increase the growth, survival and killing capacity of activated CD8 + T cells (see Figure 6E ). Interestingly, in these conditions, the ratio of activated CD8 + T cells over MM cells at day 25 was 0.13, indicating that more than 1 effector cell is needed to kill 10 MM cells. We then modified the number of tumor cells reaching the BM or their growth rate to mimic differences between batches of Vk*MYC cells ( Table 1) . As expected, if more tumor cells reached the BM or if their growth rate was increased, anti-CD137 mAb treatment lost efficacy earlier. Loss of efficacy was also observed earlier when the suppressive effect of MM on activated CD8 + T cells was increased. By contrast, MM suppressive effect on naïve CD8 + T cells only modestly modulated treatment efficacy. Finally, we tested different killing capacities of CD8 + T cells. When anti-CD137 mAb treatment had no effect on activated CD8 T cell killing capacity (i.e. it only induced the conversion of naïve into activated CD8 + T cells, increased the growth and survival of activated CD8 + T cells and thus resulted in increased numbers of activated CD8 + T cells without enhanced killing capacity), this 2-week treatment failed to eradicate the tumor when given beyond day 8. Moreover, for the treatment to be efficient beyond 4 weeks postmyeloma injection, the killing capacity of CD8 T cells had to be 10 times higher than the value set up in untreated conditions. Overall this model captures the complexity of the interactions between CD8 + T cells and MM cells and indicates that anti-CD137 mAb treatment efficacy is dependent on multiple parameters, including CD8/MM ratio, MM growth rate, MM suppressive activity and treatment ability to stimulate efficient CD8 + T cell-mediated killing. Importantly, we show that even minor modification of one of these parameters can have a dramatic impact on treatment outcome.
Treg-depletion increases BM CD8 + T cell numbers and restores the efficacy of delayed anti-
CD137 mAb treatment.
Our in silico analysis indicated that the suppressive effect of MM on CD8 + T cells influences the outcome of anti-CD137 mAb treatment. This suppressive effect can be either direct or indirect, through the induction of immune-suppressive cells such as Tregs. A recent study indicated that Tregs' immunosuppressive functions were increased in MM (26) . To assess whether Treg-mediated suppression impairs anti-CD137 mAb treatment efficacy, we first analyzed Treg responses during the course of anti-CD137 mAb treatment. We found that a single injection of anti-CD137 mAbs induced strong Treg proliferation in both tumor-naïve ( Figure 9A ) and MM-bearing mice (Supplemental Figure   9A ). There was no difference in Treg numbers obtained following CD137-stimulation between week-2and week-4-MM-bearing mice (Supplemental Figure 9B ), suggesting that Treg responses to CD137 stimulation are similar at early and late disease stages. Next, we asked whether Tregs might impair CD137-mediated activation of T cells in MM-bearing mice. We took advantage of FoxP3-DTR mice in which Tregs are depleted by the injection of diphtheria toxin (DT) (27) . At week 3 post Vk*MYC cell challenge, mice received a single DT injection followed by a single injection of anti-CD137 mAbs. We observed that DT injection alone increased CD8 + T cell numbers in the BM as well as IFNγ production by both CD4 + and CD8 + T cells and this was further enhanced when mice received a combination of Figure 9C ). To determine the impact of Treg depletion on treatment efficacy, FoxP3-DTR mice were challenged with Vk*MYC cells and 3.5 weeks later, mice received a 2-week anti-CD137 mAb treatment combined with DT injections. At week 6 post MM-challenge, we observed a significant increase in BM CD8 + T cell numbers in mice that received DT treatment alone or combined with anti-CD137 mAbs, but not in mice treated with single agent anti-CD137 mAbs (Supplemental Figure 9D ). We observed a non-significant trend toward 
DT and anti-CD137 mAbs (Figures 9B-D and Supplemental
Consolidation treatment with anti-CD137 mAbs following cyclophosphamide administration chemotherapy prolongs the survival of MM-bearing mice
We have established that tumor burden at the time of treatment is a determining factor for anti-CD137 mAb-efficacy. Thus, we investigated whether combination with cytotoxic agents that would "debulk" the tumor could restore the efficacy of delayed anti-CD137 mAb treatment. At week 3 post Vk*MYC cell challenge, mice were given an anti-CD137 mAb treatment combined with low-dose cyclophosphamide (20 mg/kg, Supplemental Figure 10A ). However, this combination did not show improved efficacy when compared with anti-CD137 mAb treatment alone. This result may be explained by the inability of lowdose cyclophosphamide to significantly reduce the tumor burden and by its immune-suppressive effects leading to reduced CD8 + T cell numbers (Supplemental Figures 10A and B) . Therefore, we next tested a sequential treatment approach. Firstly, we tested whether anti-CD137 mAbs were effective when given after cyclophosphamide treatment. At week 3 post Vk*MYC cell challenge, two groups of mice were given 2 injections of 20 mg/kg of cyclophosphamide followed by a 2-week anti-CD137 mAbtreatment or IgG-control injections (Supplemental Figure 10C ). We observed that, Direct comparison between mice receiving cyclophosphamide only and mice receiving a sequential treatment of cyclophosphamide followed by anti-CD137 mAbs indicated that, when given after cyclophosphamide injections, delayed anti-CD137 mAb treatment led to increased numbers of BM CD8 + T cells, associated with reduced tumor burden in the spleen and BM and reduced serum M-protein levels (Supplemental Figures 10A and B ). When given at higher doses (100 mg/kg), transient protection was observed with cyclophosphamide injections alone ( Figure 10C ). However, none of the mice receiving cyclophosphamide alone survived beyond day 100, in opposition to mice who received the sequential cyclophosphamide plus anti-CD137 mAb treatment ( Figure 10D ). Finally, we found that anti-CD137 mAbs improved disease control in mice that had been treated with melphalan, another chemotherapeutic commonly administered to MM patients ( Figure 11 ). Altogether, these data emphasize the unique potential of immune stimulation through anti-CD137 mAbs to allow long-term survival and suggest that anti-CD137 mAbs might have better therapeutic effect when administered as a consolidation treatment following "debulking" therapy.
Discussion
Immune-based therapies hold promise for the treatment of MM (28) . Still, the limited clinical activity of PD-1 checkpoint blockade as a single agent (5) and its toxicity when combined with IMiDs (6) emphasizes the need for better understanding of responses to immunotherapies in order to define the best timing and combination settings. In this study, we confirmed the high-therapeutic potential of anti-CD137 mAbs against MM while also demonstrating the limitations of this treatment. In the VK*MYC mouse model of MM, anti-CD137 mAb treatment failed to control advanced disease stages characterized by a high tumor burden and a decline in BM CD8 + T cell numbers. We showed that releasing Treg-mediated immunosuppression or "debulking" the tumor through chemotherapy restores the efficacy of anti-CD137 mAb treatment at advanced disease stages.
Our data provide further insights on the mechanisms of action of anti-CD137 mAbs against MM. We previously established that, in the Vk*MYC model, anti-CD137 mAb therapy requires both CD8 + T cells and NK cells (12) . Here, we demonstrated that IFNγ also contributes to the anti-MM effect of anti-CD137 mAbs, a finding which is in agreement with observations made in other tumor models (29) . IFNγ released in the context of anti-CD137 mAb therapy might either act directly on MM cells or might be necessary for the development of an efficient immune response. Our results suggest that both mechanisms contribute to the anti-MM effect of anti-CD137 mAbs. Indeed, MM grew faster in IFNγ -/mice while tumor failed to develop in IFNγR -/mice. Given that VK*MYC cells express functional receptor to IFNγ (data not shown), these data indicate that excess of IFNγ in mice lacking its receptor directly inhibits MM cell engraftment in the BM. Interestingly, CD8 + T cells were required for the protection of IFNγR -/mice against MM but IFNγR -/mice that had been depleted of CD8 + T cells still exhibited increased levels of circulating IFNγ compared to WT mice (data not shown), demonstrating that high circulating levels of IFNγ are not sufficient to control MM in the absence of CD8 + T cells. Moreover, CD8 + T cell expansion following anti-CD137 mAb treatment was compromised in both IFNγ -/and IFNγR -/mice, demonstrating that IFNγ signaling is required for the development of efficient CD8 + T cell responses to anti-CD137 mAbs. We established that NK cells constitute the first lymphocyte subset to respond to CD137 stimulation. It is possible that early IFNγ-production by NK cells is a pre-requisite to CD8 + T cell activation, as suggested by Wilcox et al. (30) .
Although the experiments performed in the present study mostly focused on the IFNγ response induced by anti-CD137 mAbs, it should be noted that this therapy is also known for increasing T cell survival and cytotoxic activity (9) . In our model, analysis of CD107a membrane expression indicated that both anti-CD137 mAb treatment and/or a high MM burden triggered CD8 + T cell degranulation (data not shown). The observation of non-significant trend toward decreased MM burden in IFNγ -/mice treated with anti-CD137 mAbs, indicates that IFNγ-independent mechanisms such as perforin/granzyme-or Fas-mediated killing of tumor cells probably contribute to the anti-MM effect of anti-CD137 mAbs.
We observed that NK cell responses to anti-CD137 mAbs were transient and that splenic NK cell numbers were dramatically reduced one week after the injection of anti-CD137 mAbs. Several The present study highlights the ability of MM cells to both induce and suppress immune responses. In mice with low MM burden, we established a positive correlation between the percentages of IFNγproducing CD8 + T cells and tumor burden, indicating that spontaneous CD8 + T cell responses are triggered by the presence of MM cells. These data are in agreement with those from Dhodapkar et al. (31) , who reported that T cells freshly isolated from the BM of patients diagnosed with monoclonal gammopathy of unknown significance (MGUS, the premalignant stage that precedes MM) are reactive against autologous premalignant cells. However, we found that, in mice with high MM burden, the correlation between IFNγ-producing CD8 + T cells and tumor burden became negative. These data are in agreement with the observation that freshly isolated BM T cells from MM patients do not present any reactivity against autologous MM cancer cells (32) , and suggest that, at advanced disease stages, the tumor becomes suppressive and inhibits the initially triggered spontaneous responses.
Given that immune responses are suppressed as MM grows, it is necessary to define the ability of immunotherapies to induce efficient immune responses in clinically active MM stages. Our data established that, even in mice with high tumor burden, T cells respond to CD137 stimulation by proliferating vigorously and secreting high amounts of IFNγ. This important information highlights the potential of anti-CD137 mAbs to reinvigorate T cell responses and to restore anti-tumor immunity even at advanced disease stages when T cells are actively repressed by the tumor. However, in this set of experiments T cell responses were investigated after a single injection of anti-CD137 mAbs and we have not ruled out the possibility that a 2-week anti-CD137 mAb treatment consisting of 4 injections may induce T cell exhaustion in advanced disease stages. In addition, several other hypotheses could explain why potent T cell responses to anti-CD137 mAbs did not translate into therapeutic activity in mice with high MM burden. We observed that the production of the immunosuppressive cytokine IL10 increases as MM grows, and this might contribute to repress T cell responses to anti-CD137 mAbs in vivo. Moreover, at advanced MM stages, we observed a drastic decline in total immune cell numbers in the BM (not shown). Notably, CD8 + T cell numbers were dramatically reduced in mice with high MM burden prior to anti-CD137 mAb treatment and the fold increase in CD8 + T cell numbers post-CD137 stimulation was lower at advanced disease stages. We propose that the lack of efficacy of anti-CD137 mAbs at late disease stages is due to the inability of this therapy to expand sufficient numbers of CD8 + T cells, leading to an insufficient CD8/MM ratio. Doban et al. (25) have proposed a dynamical model that considers the interactions between tumor cells, resting (i.e. naïve) and hunting (i.e. activated) immune cells through predator-prey competition terms. We adapted this model to fit our experimental data and study the interactions between CD8 + T cells and MM cells in Vk*MYC cell-injected mice. Notably, we introduced a CD8 + T cell contraction term associated with a new population of exhausted CD8 + T cells; this was necessary for the system to return to steady-state conditions after eradication of the tumor. Moreover, we used delay differential equations (with discrete delays) to account for time-delays in CD8 + T cell activation, CD8 + T cell contraction and tumor dormancy. We also incorporated new parameters to distinguish between tumor-induced and immunotherapy-induced activation of CD8 + T cells. This new model allowed us to evaluate the impact of various parameters (MM growth rate, CD8 + T cell proliferation rate, CD8 + T cell activation rate, CD8 + T cell killing capacity, MM-immunosuppressive effect) on immunotherapy efficacy. We believe that the present model is suitable for the analysis of immune cell-tumor cell interactions in most cancer types and provides a useful tool for cancer immunologists.
We found that releasing immunosuppression through Treg-depletion increased BM CD8 + T cell numbers and restored the efficacy of anti-CD137 mAbs against advanced MM disease. Although these findings suggest that immune-checkpoint blockade would be efficient in these settings, anti-CD137 mAb combination with anti-CTLA4 or anti-PD-1 mAbs did not show improved efficacy against advanced Vk*MYC MM tumors compared to anti-CD137 mAb as a single agent. These results are disappointing given the promising potential of combining CD137-stimulation with PD-1/PD-L1 blockade in solid tumors (33) . Nevertheless, it was recently reported that PD-1 blockade abrogates the therapeutic efficacy of anti-CD137 mAbs in the Eμ-MYC model of mouse lymphoma (34) . In agreement with this last report, our data emphasize the need for a better understanding of the underlying immune responses to combination therapies to define the specific cancer types and conditions where they might be beneficial.
Moreover, we recently identified TIGIT as a dominant negative regulator of CD8 + T cell responses against MM (35, 36) . Since TIGIT is expressed at higher levels than PD-1 or CTLA-4 on BM CD8 + T cells from MM patients (35) , we suggest that combination of CD137 costimulation together with TIGIT blockade should be explored in MM.
We observed that anti-CD137 mAb treatment improved MM control when administered after chemotherapy with either cyclophosphamide or melphalan. Although low doses of cyclophosphamide are known for depleting Tregs (37), we observed no reduction in Treg numbers in the BM and spleen of mice treated with low dose cyclophosphamide (20 mg/kg). Since delayed anti-CD137 mAb treatment was also efficient after treatment with high dose cyclophosphamide or with the myeloablative agent melphalan, we do not think that modulation of Treg responses is instrumental for the success of sequential therapy. Instead, our data suggest that tumor 'debulking' leading to increased CD8/MM ratio is the main mechanism by which chemotherapy with cyclophosphamide or melphalan restores the efficacy of delayed anti-CD137 mAb treatment.
The identification of biomarkers of responses and the definition of optimal timing is of primary importance for the clinical development of immunotherapies. Here, we showed that M-protein measurement predicts response to anti-CD137 mAb immunotherapy. Therefore, we suggest that anti-CD137 mAbs should be administered to eradicate residual tumor cells after 'debulking' strategies. Accordingly, CD137 costimulation was found to promote long-term survival after autologous stem cell transplantation in the Vk*MYC MM model (38) . Collectively, our data provide rationale for clinical trials to evaluate anti-CD137 mAbs as a consolidation treatment for MM patients with minimal residual disease.
Methods
Mice. All mice used in this study were on a C57BL/6 genetic background. C57BL/6 WT mice were purchased from the Walter and Eliza Hall Institute for Medical Research, bred in house at QIMR Berghofer Medical Research Institute or purchased from Janvier. C57BL/6, Rag2 -/-Il2rγ2 -/-, Ifnγ -/-, Ifnγr -/-, Ifnar -/and Foxp3-DTR mice have been previously described (12, 27, 39, 40) Anti-MM therapy. Mice receiving a 2-week anti-CD137 mAb treatment were injected i.p. with 100 μg of anti-CD137 mAbs (rat IgG2a, 3H3, BioxCell) or control rat IgG2a, twice a week for 2 weeks. In some experiments, mice received a single i.p. injection of 100 μg of anti-CD137 mAbs or control rat IgG2a.
To deplete Tregs, 250 ng of diphtheria toxin (DT; Sigma-Aldrich) were administered i.p. to C57BL/6
FoxP3-DTR mice, as previously described (27); control mice were injected with PBS. 
